Ironwood Pharmaceuticals Inc (IRWD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $802.92M
Last updated: Nov 17, 2026 at 4:34 PM ET
Ironwood Pharmaceuticals Inc (IRWD) Statistics
Ironwood Pharmaceuticals (IRWD) has a market cap of $802.92M and an enterprise value of $1.05B. Its return on invested capital of 70.49% compares with a 7.96% median across 8 similar companies. It kept 37.38% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 30.70% above the market cap, as debt exceeds cash.
| Market Cap | $802.92M |
|---|---|
| Enterprise Value | $1.05B |
| Latest price (Nov 17, 2026) | $4.87 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 2.0x. Its year-end P/E ranged from 9.9x to 303.4x from 2019 to 2025.
| P/E Ratio | 5.4x |
|---|---|
| Forward P/E | 3.8x |
| P/S Ratio | 2.0x |
| Forward P/S | 1.6x |
| P/OCF Ratio | 3.9x |
| PEG Ratio | 0.3 |
Enterprise Valuation
Counting debt and cash, the company is valued at 4.1x EBITDA.
| EV / Earnings | 7.0x |
|---|---|
| EV / Sales | 2.6x |
| EV / EBITDA | 4.1x |
| EV / EBIT | 4.2x |
Price Statistics
The stock is up 55.10% over 52 weeks and trades 22.06% above its 50-day average.
| Beta (1Y) | 1.30 |
|---|---|
| 52-Week Change | +55.10% |
| 1-Month Change | +36.80% |
| 3-Month Change | +11.70% |
| 6-Month Change | +32.70% |
| 5-Year Change | -72.59% |
| 10-Year Change | -72.59% |
| Total Return (1Y) | +55.10% |
| Total Return (3Y CAGR) | -20.73% |
| Total Return (5Y CAGR) | -16.35% |
| Return vs SPY (1Y) | +45.03% |
| Max Drawdown (1Y) | -43.60% |
| Max Drawdown (3Y) | -96.33% |
| Sharpe Ratio (1Y) | 0.59 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $3.99 |
| 200-Day Average | $3.95 |
| 52-Week Range | $2.95 to $5.78 |
| RSI (14 Days) | 75.6 |
| Average Volume (20 Days) | 2.53M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.51x current liabilities.
| Current Ratio | 6.51x |
|---|---|
| Quick Ratio | 6.51x |
| Debt / EBITDA | 1.31x |
| Interest Coverage | 8.28x |
Returns and Efficiency
Return on invested capital is 70.49% over the last 12 months, against a 5-year average of -37.94%.
| Return on Assets (ROA) | 51.49% |
|---|---|
| Return on Invested Capital (ROIC) | 70.49% |
| Return on Capital Employed (ROCE) | 98.50% |
| ROA (5Y Average) | -29.98% |
| ROIC (5Y Average) | -37.94% |
| Asset Turnover | 1.17x |
| Receivables Turnover | 3.26x |
Taxes
Income tax took 34.07% of pretax income over the last 12 months.
| Income Tax (TTM) | $77.33M |
|---|---|
| Effective Tax Rate | 34.07% |
Scores
IRWD has an Altman Z-Score of -1.06, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.06 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $400.30M over the last 12 months is up 18.09% from the 12 months before.
| Revenue | $400.30M |
|---|---|
| Revenue Growth (YoY) | +18.09% |
| Gross Profit | $400.30M |
| Operating Income | $251.82M |
| Pretax Income | $226.95M |
| Net Income | $149.63M |
| EBITDA | $253.84M |
| EBIT | $252.02M |
| Reported EPS (TTM) | $0.90 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $86.38M |
|---|---|
| Total Debt | $332.91M |
| Net Debt | $246.53M |
| Net Debt Per Share | $1.50 |
| Working Capital | $191.26M |
| Shareholder Equity | -$97.19M |
| Tangible Book Value | -$98.62M |
| Total Assets | $290.59M |
| Total Liabilities | $387.79M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $205.37M |
|---|---|
| FCF Per Share | $1.24 |
| Depreciation and Amortization | $1.82M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 62.91%, against a 5-year average of -7.34%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | 62.91% |
| Pretax Margin | 56.70% |
| Net Margin | 37.38% |
| EBITDA Margin | 63.41% |
| EBIT Margin | 62.96% |
| Operating Margin (5Y Average) | -7.34% |
| Net Margin (5Y Average) | -10.86% |
Growth
Revenue fell 10.32% a year over 3 years, and EPS 38.11% a year.
| Revenue Growth (3Y CAGR) | -10.32% |
|---|---|
| Revenue Growth (5Y CAGR) | -5.33% |
| EPS Growth (3Y CAGR) | -38.11% |
| EPS Growth (5Y CAGR) | -21.87% |
| FCF Growth (3Y CAGR) | -22.57% |
| FCF Growth (5Y CAGR) | -5.33% |
| Operating Income Growth (3Y CAGR) | -26.72% |
Dividends and Yields
IRWD does not pay a dividend.
| Earnings Yield | 18.52% |
|---|---|
| Buyback Yield | -0.05% |
| Shareholder Yield | -0.05% |
Peer Position
Against 9 similar companies, IRWD has the 8th highest P/E.
P/E RatioPeer median 12.8x
P/S RatioPeer median 2.0x
ROICPeer median 7.96%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +12.08%
| P/E Ratio | 5.4x vs 12.8x median |
|---|---|
| P/S Ratio | 2.0x vs 2.0x median |
| ROIC | 70.49% vs 7.96% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +18.09% vs +12.08% median |
Analyst Forecast
Consensus estimates put revenue growth at 30.48% and EPS growth at 160.99% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +30.48% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +160.99% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IRWD
What is IRWD's market cap?
Ironwood Pharmaceuticals has a market cap of $802.92M. Its enterprise value, which adds debt and subtracts cash, is $1.05B.
What is IRWD's P/E ratio?
Ironwood Pharmaceuticals has a trailing P/E ratio of 5.4x and a forward P/E of 3.8x.
How many shares of IRWD are outstanding?
Ironwood Pharmaceuticals has 164.90M shares outstanding. The count is up 1.65% from a year earlier.
Does IRWD pay a dividend?
No. Ironwood Pharmaceuticals does not pay a dividend.
How much debt does IRWD have?
Ironwood Pharmaceuticals has $332.91M of total debt and $86.38M of cash and equivalents, a net debt position of $246.53M.
IRWD pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors